



News Release

Suven's Income at Rs. 2020 Mn; PAT at Rs. 571 Mn for the quarter ended June 2019

HYDERABAD, INDIA (14 Aug' 2019) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2019. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Aug 2019 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2019: (QoQ)

Growth in revenue	INR 2020 Mn vs. INR 2570 Mn - Down by 21.42%
Growth in PAT	INR 571 Mn vs. INR 680 Mn - Down by 16.02%
Growth in EBIDTA	INR 930 Mn vs. INR 1090 Mn - Down by 14.68%

Financial Highlights (comparison with same quarter, previous year):

Growth in revenue	INR 2020 Mn vs. INR 1998 Mn - Up by 1.10%
Growth in PAT	INR 571 Mn vs. INR 388 Mn - Up by 47.38%
Growth in EBIDTA	INR 930 Mn vs. INR 664 Mn - Up by 40.21%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 131 Mn (6.49% on revenue) for the quarter ended 30th June 2019.

Update on patents during this period can be viewed at: <http://suven.com/Patentupdates.aspx>

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;